Price Chart
Key Statistics
Market Cap(EOD)224.43M
Enterprise Value89.41M
P/E Ratio (TTM)-10.19
P/B Ratio (TTM)4.86
P/S Ratio (TTM)0.00
Earnings Yield (TTM)-9.81%
ROE (TTM)-44.71%
ROIC (TTM)-60.35%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.00
About Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.